ACLY depletion with small interfering RNA or the small-molecule inhibitor GSK165 promotes HT29 chemosensitivity to SN38, indicating that ACLY amplifies irinotecan resistance in CRC [167]. The gene discussed is ACLY; the disease is colorectal carcinoma.